Trial Profile
A Randomized, Multicenter Clinical Trial to Determine the Efficacy, Safety and Tolerability of Peg-filgrastim (Gema) Compared to Peg-filgrastim (Roche) for Prevention of Chemotherapy Induced Neutropenia in Patients With Breast Cancer
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Pegfilgrastim (Primary)
- Indications Febrile neutropenia
- Focus Therapeutic Use
- Sponsors GEMA
- 04 Jun 2019 Results assessing efficacy and safety of pegfilgrastim for prevention of chemotherapy induced neutropenia published in conjunction with 55th Annual Meeting of the American Society of Clinical Oncology (2019)
- 22 Jan 2018 New trial record